PIK3CA and breast cancer: The phase III placebo-controlled SOLAR-1 trial randomized 572 patients with endocrine-resistant advanced breast cancers who had received prior AI in the neoadjuvant/adjuvant or metastatic settings, including 341 patients with PIK3CA mutation, to fulvestrant with either alpelisib or placebo.